Published in Prostate on May 01, 2010
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc Natl Acad Sci U S A (2012) 1.26
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
Mouse models of prostate cancer. Prostate Cancer (2011) 1.04
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
Weighted change-point method for detecting differential gene expression in breast cancer microarray data. PLoS One (2012) 0.81
In vitro and in vivo model systems used in prostate cancer research. J Biol Methods (2015) 0.81
Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells. Biochim Biophys Acta (2011) 0.81
Type II transmembrane serine proteases as potential targets for cancer therapy. Biol Chem (2016) 0.76
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene (2015) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
MYC oncogenes and human neoplastic disease. Oncogene (1999) 7.28
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol (1995) 3.39
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology (2000) 2.69
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Unusual subtypes of prostate cancer. Mod Pathol (2004) 2.20
Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol (2002) 1.96
Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch (1995) 1.91
Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 1.89
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol (2001) 1.87
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res (2001) 1.59
Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem (2002) 1.40
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res (1986) 1.25
Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer (2005) 1.22
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem (2008) 1.14
Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol (2001) 1.11
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol (2004) 1.11
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol (2003) 1.08
Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol (1997) 1.07
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res (2006) 1.05
Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res (1997) 1.00
Emerging roles for proteinases in cancer. Invasion Metastasis (1997) 1.00
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol (2005) 0.98
Hepsin and prostate cancer. Front Biosci (2007) 0.97
Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature. Cancer (1984) 0.95
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone (2007) 0.91
The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours and non-tumour prostate. Histochemical and ultrastructural identification of the endocrine cells. Histopathology (1981) 0.88
Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate-specific antigen. Am J Surg Pathol (1984) 0.86
Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol (1990) 0.82
Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med (1984) 0.81
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Actin cable dynamics and Rho/Rock orchestrate a polarized cytoskeletal architecture in the early steps of assembling a stratified epithelium. Dev Cell (2002) 4.01
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway. Science (2006) 3.09
Loss of cell polarity causes severe brain dysplasia in Lgl1 knockout mice. Genes Dev (2004) 2.55
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res (2007) 2.22
α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal (2011) 2.05
Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 1.89
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res (2005) 1.79
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
Cell polarity and cancer--cell and tissue polarity as a non-canonical tumor suppressor. J Cell Sci (2008) 1.73
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene (2002) 1.71
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res (2006) 1.55
Adhesive and signaling functions of cadherins and catenins in vertebrate development. Cold Spring Harb Perspect Biol (2009) 1.52
MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One (2011) 1.38
Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol Cell Biol (2006) 1.33
Failure of epithelial tube maintenance causes hydrocephalus and renal cysts in Dlg5-/- mice. Dev Cell (2007) 1.33
Cadherin-catenin proteins in vertebrate development. Curr Opin Cell Biol (2006) 1.31
Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate (2009) 1.30
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood (2005) 1.23
A novel circular invasion assay mimics in vivo invasive behavior of cancer cell lines and distinguishes single-cell motility in vitro. BMC Cancer (2008) 1.21
Microenvironmental independence associated with tumor progression. Cancer Res (2009) 1.13
Trait variability of cancer cells quantified by high-content automated microscopy of single cells. Methods Enzymol (2009) 1.10
CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia (2007) 1.10
Coupled analysis of gene expression and chromosomal location. Genomics (2005) 1.10
PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity. J Biol Chem (2008) 1.02
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
Alpha-E-catenin binds to dynamitin and regulates dynactin-mediated intracellular traffic. J Cell Biol (2008) 0.99
Laminin-332-beta1 integrin interactions negatively regulate invadopodia. J Cell Physiol (2010) 0.98
Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology (2006) 0.97
Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer (2010) 0.97
The role of forkhead box A2 to restrict androgen-regulated gene expression of lipocalin 5 in the mouse epididymis. Mol Endocrinol (2006) 0.95
Loss of Llgl1 in retinal neuroepithelia reveals links between apical domain size, Notch activity and neurogenesis. Development (2012) 0.94
Mammalian Llgl2 is necessary for proper branching morphogenesis during placental development. Mol Cell Biol (2011) 0.90
Epitope mapping of function-blocking monoclonal antibody CM6 suggests a "weak" integrin binding site on the laminin-332 LG2 domain. J Cell Physiol (2010) 0.89
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells. Prostate (2011) 0.89
Dlg5 maintains apical aPKC and regulates progenitor differentiation during lung morphogenesis. Dev Biol (2013) 0.88
Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues. Genesis (2006) 0.87
Inhibition of stathmin1 accelerates the metastatic process. Cancer Res (2012) 0.87
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget (2014) 0.87
E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc Natl Acad Sci U S A (2010) 0.86
alphaE-catenin is not a significant regulator of beta-catenin signaling in the developing mammalian brain. J Cell Sci (2008) 0.86
Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol (2012) 0.86
Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis. Thromb J (2006) 0.85
Nest expansion assay: a cancer systems biology approach to in vitro invasion measurements. BMC Res Notes (2009) 0.85
The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol (2010) 0.84
Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control (2007) 0.84
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet (2011) 0.83
Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer. Mol Cytogenet (2009) 0.83
The imperative to invest in science has never been greater. J Clin Invest (2014) 0.82
Lysophosphatidic Acid Upregulates Laminin-332 Expression during A431 Cell Colony Dispersal. J Oncol (2010) 0.81
Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Clin Appl Thromb Hemost (2007) 0.80
Characterization of three Staphylococcus aureus isolates from a 17-year-old female who died of tampon-related toxic shock syndrome. J Clin Microbiol (2010) 0.80
Dissecting the role of cadherin-catenin proteins in mammalian epidermis. Proc Natl Acad Sci U S A (2008) 0.79
The role of a recombinant fragment of laminin-332 in integrin alpha3beta1-dependent cell binding, spreading and migration. Biomaterials (2010) 0.79
Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant (2007) 0.79
Development of high-throughput quantitative assays for glucose uptake in cancer cell lines. Mol Imaging Biol (2011) 0.79
Migration of isogenic cell lines quantified by dynamic multivariate analysis of single-cell motility. Cell Adh Migr (2009) 0.79
Your gut is right to turn left. Dev Cell (2013) 0.77
Loss of heterozygosity of succinate dehydrogenase B mutation by direct sequencing in synchronous paragangliomas. Cancer Genet Cytogenet (2009) 0.75
Planar cell polarity planes the inconveniences of cell division into a smooth morphogenetic process. Dev Cell (2006) 0.75
Cellular neurothekeoma of the chest wall. Med Pediatr Oncol (2002) 0.75
Orbital pleomorphic liposarcoma in an eight-year-old boy. Pediatr Dev Pathol (2011) 0.75